ARASENS trial with darolutamide in combination with docetaxel and androgen deprivation therapy meets primary endpoint of significantly increasing overall survival in patients with metastatic hormone-sensitive prostate cancer
December 03, 2021 01:30 ET
|
Orion Oyj
ORION CORPORATION STOCK EXCHANGE RELEASE / INSIDE INFORMATION3 DECEMBER 2021 at 8.30 EET ARASENS trial with darolutamide in combination with docetaxel and androgen deprivation...
Global Castrate Resistant Prostate Cancer (CRPC) Market to Surpass US$ 16.4 Billion by 2028, Says Coherent Market Insights (CMI)
July 20, 2021 08:40 ET
|
CMI
SEATTLE, July 20, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global castrate-resistant prostate cancer market is estimated to be valued at US$ 9.5 billion in 2021 and is...
Orion Group Half-Year Financial Report 1-6/2021
July 19, 2021 05:00 ET
|
Orion Oyj
ORION CORPORATION HALF-YEAR FINANCIAL REPORT 1-6/2021 19 JULY 2021 at 12:00 noon EEST Orion Group Half-Year Financial Report 1-6/2021 This is a summary of Orion’s Half-Year Financial...
Orion Group Interim Report 1-3/2021
April 27, 2021 05:00 ET
|
Orion Oyj
ORION CORPORATION INTERIM REPORT 1-3/2021 27 APRIL 2021 at 12:00 noon EEST Orion Group Interim Report 1-3/2021 This is a summary of Orion’s Interim Report 1-3/2021. The complete report...
Global Castrate-resistant Prostate Cancer Market By Therapy, By Region, Industry Analysis and Forecast, 2020 - 2026
February 10, 2021 07:14 ET
|
ReportLinker
New York, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Castrate-resistant Prostate Cancer Market By Therapy, By Region, Industry Analysis and...
US Prostate Cancer Drug Market Outlook to 2026: Comprehensive Clinical Insight on 25 FDA Approved Prostate Cancer Drugs
February 10, 2021 03:38 ET
|
Research and Markets
Dublin, Feb. 10, 2021 (GLOBE NEWSWIRE) -- The "US Prostate Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering. ...
Orion Group Financial Statement Release for 2020
February 09, 2021 05:00 ET
|
Orion Oyj
ORION CORPORATION FINANCIAL STATEMENT RELEASE 2020 9 FEBRUARY 2021 at 12:00 Orion Group Financial Statement Release for 2020 This is a summary or Orion’s Financial Statement...
Orion and Bayer expand development program for darolutamide in prostate cancer
February 08, 2021 07:00 ET
|
Orion Oyj
ORION CORPORATION PRESS RELEASE 8 FEBRUARY 2021 at 14.00 EET Orion and Bayer expand development program for darolutamide in prostate cancer Phase III study ARANOTE...
Orion Group Interim Report 1-9/2020
October 21, 2020 05:00 ET
|
Orion Oyj
ORION CORPORATION INTERIM REPORT 1-9/2020 21 OCTOBER 2020 at 12:00 noon EEST Orion Group Interim Report 1-9/2020 This is a summary of Orion’s Interim Report 1-9/2020. The...
New England Journal of Medicine publishes final overall survival data for darolutamide showing treatment significantly extends life in men with non-metastatic prostate cancer
September 10, 2020 00:30 ET
|
Orion Oyj
ORION CORPORATION PRESS RELEASE 10 SEPTEMBER 2020 at 7.30 EEST New England Journal of Medicine publishes final overall survival data for darolutamide showing treatment...